We’re building an engine for warp speed drug development

Alvea is a technology company dedicated to dramatically reducing the time from molecule to trials for new medicines. The world badly needs this capacity to stop future pandemics in their tracks and unlock the impact of biotechnology advances on human health.

Our Mission /

To Break Open the Bottlenecks that Will Impede the World’s Ability to Benefit from Revolutionary Drug Design

We’re a team of drug designers, software engineers, clinical development experts, physicians, and operators working to radically accelerate the development of new medicines for pandemics and beyond.

We work with partners at the cutting edge of drug design and discovery to in-house, automate, and re-engineer rate-limiting workflows, getting products to patients—and the market—faster than ever before.

Leadership /

Our teammates, funders, and advisers are world-leading experts in biotechnology, pandemic prevention, clinical development.  See our full team here.
21
Grigory Khimulya
CEO
20
Cate Hall
COO
596
Maximilian Schons
CMO
22
Kyle Fish
CTO

Advisors /

19
Ethan Alley
Board Member
488
Blake Borgeson
Board Member
17
Kevin Esvelt
Advisor
491
John Donnelly
Advisor
723
Penny Moore
Advisor

Backed By /

Careers /

We’re seeking motivated, fast-moving people with a broad range of backgrounds and specialties.

If you think you’d be a good fit, or you want to hear more about opportunities at Alvea, please get in touch.

Latest News /

See all Alvea news →
Want to talk? Email us at —
info@alvea.bio